Lonza reports CHF 3.03 billion in sales amid divestment of Capsules & Health Ingredients unit

As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%

Lonza, Antharis partner to develop next-generation dual-payload ADCs for GI cancers

Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise

AmMax Bio licenses Lonza’s ADC tech to advance AML candidate AMB-104

The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027

Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies

Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments

Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds

Lonza launches Singapore Media Development Lab to cut biomanufacturing risk

The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes

Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO

Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

Lonza to set up Global Capability Centre in Hyderabad

Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process